Korean J Vet Res.  2021 Mar;61(1):e10. 10.14405/kjvr.2021.61.e10.

Retrospective evaluation of toceranib phosphate (Palladia) for treatment of different tumor types in 31 dogs

• Choi SI
• Nam YL
• Kim JK
• Park HJ
• Song KH
• Seo KW

• KMID: 2514733
• DOI: http://doi.org/10.14405/kjvr.2021.61.e10

Abstract

The purpose of this retrospective study was to provide additional data on the use of toceranib in a wide variety of tumor types in small breed dogs, especially < 8 kg (except 5 dogs). This was a retrospective study of 31 dogs with malignant tumors treated with a 2.5 mg/kg median dose of toceranib (Palladia; Zoetis, Florham Park, NJ, USA) on a Monday–Wednesday–Friday schedule. Clinical benefit was observed in 13 of 15 dogs (86.7%, 3 with complete response, 4 with partial response, 6 with stable disease) with gross disease. Distant metastasis, response to treatment, and treatment setting were significantly associated with survival time. Negative prognostic factors were multiple chemotherapy and distant metastasis (affecting progression-free survival [PFS]), surgery, regional enlarged lymph nodes, underlying disease, and toxicity (affecting median survival time [MST]). Positive prognostic factors were epithelial and round cell tumor (affecting PFS), epithelial tumor, microscopic disease, no evidence of disease response, and stable disease (MST). In conclusion, a clinical benefit from toceranib treatment was noted in most of the dogs with gross disease in our study. This study suggested that the toceranib is probably selective treatment to various tumor types in small breed dogs.

Keyword

canine; neoplasms; Palladia; toceranib phosphate; tyrosine kinase inhibitor